Company intelligence / Profile preview

Adimune

Ownership: Private
Development stage: Preclinical

Overview

Adimune’s ADI platform shows preclinical efficacy in models of skin grafting, psoriasis, type 1 diabetes, and alopecia areata. There is no clinical data published yet, but the company claims selective immune tolerance via apoptotic DNA technology and has signed early-stage co-development agreements with major pharmaceutical partners.

Therapeutic areas: DermatologyImmunologyEndocrinology
Modalities: DNA therapyPlasmid DNA-based therapy
Industry: Biotech

Drug pipeline

2 assets

ADI-100

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

Early-stage co-development agreements with undisclosed major pharmaceutical companies

Beyond the preview

Go deeper on Adimune.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Adimune.

Explore the full profile